Citadel Advisors’s Amplify Weight Loss Drug & Treatment ETF THNR Stock Holding History

Citadel Advisors’s Portfolio THNR Stock Details THNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$706K	Buy	27,493 +252	+0.9%	+$6.2K	﹤0.01%	9058
2026 Q1	$670K	Buy	+27,241	New	+$694K	﹤0.01%	8592

Other funds holding THNR

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

GFA

Godfrey Financial Associates Glenmont, New York $131M AUM

Citadel Advisors's THNR Position: Q2 2026 in Review

Citadel Advisors increased its Amplify Weight Loss Drug & Treatment ETF (THNR) stake by 0.93% in Q2 2026, buying an estimated $6.2K and bringing the position to 27,493 shares worth $706K. The position accounts for ﹤0.01% of the portfolio, ranked #9058.

Citadel Advisors first reported a position in THNR in Q1 2026 and has held it in 2 quarters since. 4 funds tracked by Wall St. Rank hold THNR as of Q2 2026.

Citadel Advisors held 27,493 shares of Amplify Weight Loss Drug & Treatment ETF worth $706K as of Q2 2026.
Citadel Advisors bought 252 Amplify Weight Loss Drug & Treatment ETF shares in Q2 2026, an estimated $6.2K.
Amplify Weight Loss Drug & Treatment ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #9058 holding.
Citadel Advisors first reported a position in Amplify Weight Loss Drug & Treatment ETF in Q1 2026 and has held it in 2 quarters since.
4 funds tracked by Wall St. Rank held Amplify Weight Loss Drug & Treatment ETF as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.